The Etidronate Legacy

ZY-001 builds on the long-established safety and efficacy of etidronate (disodium etidronate), a first-generation bisphosphonate used for more than four decades to treat disorders of abnormal mineralization.

While etidronate demonstrated a clear mechanism of action in binding calcium, its original formulation was not designed for neurological applications. Its low bioavailability (~3%) and limited CNS penetration prevented it from reaching therapeutic concentrations in the brain.

Zy Therapeutics is re-engineering etidronate using advanced microencapsulation and absorption-enhancement technologies to overcome these barriers, aiming to enable therapeutic concentrations in the brain for the first time.